Bharat Parenterals shareholders approve preferential issue and Section 186 limits

The resolutions in numbers

Both resolutions passed with unanimous votes cast

Both special resolutions passed with 4,879,194 votes in favour and no votes against, which the scrutinizer's report counts as 100% of valid votes cast. Those votes were 70.7954% of the 6,891,963 shares outstanding for voting, so the remaining shares did not vote on either item.

Only 69 members voted remotely and none voted at the EGM, according to the scrutinizer's breakdown. The meeting had 28 shareholders attending by video conferencing, 5 from the promoter and promoter group and 23 from the public, out of 3,757 shareholders on the record date.

Promoter interest and the approval process

The company says neither resolution was proposed with promoter or promoter group interest. Jigar Trivedi of Jigar Trivedi & Co., Practising Company Secretaries, was appointed scrutinizer by the Board on 29 Sep 2026 and issued the report on 24 Oct 2026.

The EGM notice is dated 1 Oct 2026 and was read with a corrigendum dated 13 Oct 2026. The voting results and the scrutinizer's report are placed on the company's website and on the NSDL website.

What the approvals mean for Bharat Parenterals' shareholders

The approvals give the company shareholder authority to issue equity shares on a preferential basis and to exceed Section 186(2) limits on investments, loans, guarantees and security. The filing does not state the number of shares or the issue price of the preferential issue, the allottees, the purpose of the funds, or the amount the Section 186(2) approval covers. It also does not say whether or when shares will be allotted.

The filing sets no further dated step beyond the publication of the voting results. Its effect on the company's capital depends on terms not yet disclosed in the filing.

Reference: Original filing (PDF)